Austedo xr and austedo are the first vesicular monoamine transporter 2 (vmat2) inhibitors approved by the u.s Food and drug administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with huntington’s disease. In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment. The routine use of benzodiazepines should be discouraged Because tardive dyskinesia most commonly develops after exposure to antipsychotics. Austedo, with the generic name deutetrabenazine, is a medication specifically designed for managing movement disorders such as chorea associated with huntington's disease and tardive dyskinesia
Many individuals facing these disorders often seek information on treatment options that can improve their quality of life. Significant improvements in tardive dyskinesia symptoms and patient quality of life were observed Teva's financial metrics indicate a mixed performance with strong operating margins but challenges in revenue growth
WATCH
